在北歐創新高地，藥明康德向全球合作致敬！| Bilingual

在瑞典西海岸的哥德堡，新地標沃爾沃博物館（World of Volvo）見證了一場關于創新與合作的思想碰撞——“藥明之夜”。這座展館是瑞典汽車工業精神的象征，詮釋著對創新、品質、關懷、可持續發展的追求和傳承。這份精神與生命科學行業的核心理念不謀而合：以創新守護生命，以品質驅動信任。

正如沃爾沃博物館所代表的文化底色，哥德堡的骨子里自維京時代起便鐫刻著探索與開拓的基因。它不僅是瑞典通向世界的航運門戶，也是北歐的生物科技重鎮。以阿斯利康為代表的全球藥企在醫藥園區為業界注入源源不斷的智慧與靈感，數百家生命科學領域的新銳公司亦在此扎根。

這一迸發出蓬勃活力的創新生態，離不開北歐地區強大的開放合作精神。本周，2025年北歐生命科學日（Nordic Life Science Days 2025）在哥德堡召開。來自歐洲乃至全球的同仁相聚于此，致力合作為病患帶來改變生命的創新療法。作為主辦方瑞典生物技術行業組織（SwedenBIO）的合作伙伴，藥明康德也在會議期間延續傳統，攜手全球產業資深人士探討創新前沿與合作機遇，共度令人難忘的“藥明之夜”。

SwedenBIO致力于匯聚全產業鏈的關鍵參與者，推動醫療創新成果轉化，改善全球人類健康。其首席執行官Jessica Martinsson女士在致辭中表示，SwedenBIO得到了來自藥明康德等合作伙伴的有力支持，她對此深表感激，并強調全球合作對于創新發展的重要意義。她也進一步指出，北歐在歷史上曾是一個統一的國家，彼此分享著同樣的文化與血脈，這奠定了合作的基礎。以哥德堡為例，這座城市如今正積極推動潛力企業從高質量的學術機構中孵化成長，成為瑞典生命科學領域的新興力量。得益于這種開放協作的創新文化，生命科學產業已成為瑞典重要的經濟支柱之一，其出口貢獻甚至超過傳統的汽車工業，充分展現出北歐生命科學生態的強勁活力。

藥明康德新藥發現業務副總裁Dave Madge博士，以及德國慕尼黑基地負責人Thomas Meins博士也在藥明之夜上指出行業生態正在不斷演進。一方面，越來越多的創新成果源自早期科研機構和新興生物技術公司；另一方面，寡核苷酸、多肽等新分子類型不斷涌現，進一步拓展了創新的邊界。這些趨勢推動了行業間的協作，也讓藥明康德有幸為大量新藥研發賦能。藥明康德在美國和歐洲的研發與生產基地將持續投入新技術和新平臺的建設，更好地支持全球不同規模醫藥企業的創新需求。

藥明康德副總裁蔡輝博士代表公司向在場的嘉賓和產業領袖表達誠摯感謝。她提到，行業今日取得的進步，離不開持續的技術創新以及生態圈通力合作。今年是藥明康德成立的25周年。自成立以來，“讓天下沒有難做的藥，難治的病”始終是藥明康德秉持的愿景。

匠人匠心，如果說SwedenBIO在致力打造充滿合作精神的北歐生態圈，產業界的每一位同仁在致力打造造福患者的療法，那么藥明康德就在致力打造更好地賦能產業合作伙伴的平臺。同行致遠，我們相信彼此之間的信任與合作，將加速更多創新療法的問世，為全球病患帶來更光明的未來。

WuXi Night Gothenburg: A Celebration of Global Partnerships

On Sweden’s west coast in Gothenburg, at the new icon of the city, the World of Volvo hosted WuXi AppTec’s “WuXi Night,” a gathering of ideas and collaboration. As a symbol of Sweden’s automotive heritage, the museum reflects a legacy of innovation, quality, care, and sustainability, values that closely align with the life science industry: creating trust, improving well-being, and never losing sight of the patients we serve.

Gothenburg itself carries a legacy of exploration and innovation dating back to the Viking era. As Sweden’s gateway to the world, the city is today not only a vital shipping hub but also a leading biotechnology center in Northern Europe. Global pharmaceutical companies like AstraZeneca and hundreds of life science biotech companies make Gothenburg one of the region’s most dynamic innovation clusters.

At the heart of this momentum lies the Nordic tradition of openness and collaboration. This week, the region’s largest life science partnering event, Nordic Life Science Days 2025 (NLSDays), was held in Gothenburg by SwedenBIO, bringing together experts and organizations from across Europe and around the world to forge partnerships that deliver life-changing therapies to patients.

As a partner of SwedenBIO, WuXi AppTec continued its tradition and hosted the much-anticipated “WuXi Night,” where industry leaders and partners from around the globe gathered for an evening of insightful discussion on innovation and collaboration.

Jessica Martinsson, CEO of SwedenBIO, expressed her gratitude for the strong support from partners such as WuXi AppTec, and emphasized the vital role of global collaboration in advancing innovation. Since its inception in 2013, NLSDays has aimed to promote dialogue and partnership between Nordic companies and their global counterparts, fostering the continued growth of the life science ecosystem. Martinsson noted that the spirit of collaboration is deeply rooted in Nordic history. Today, Gothenburg is catalyzing a powerful synergy between world-class academic institutions and a multitude of innovation-driven startups, positioning the city to play a crucial role in nurturing these emerging enterprises.

Thanks to this open, cooperative culture, life science have become one of Sweden’s key economic pillars, with sector exports now surpassing even the traditional automotive industry, a striking reflection of the Nordic life science ecosystem’s strength and vitality.

During the event, Dr. Dave Madge, Vice President of Research Service Division at WuXi AppTec, and Dr. Thomas Meins, Head of WuXi AppTec’s Munich site, highlighted the industry’s evolving landscape. Increasingly, breakthroughs are emerging from early-stage research institutes and innovative biotech companies, while new therapeutic modalities such as oligonucleotides and peptides are expanding the frontiers of medicine. These trends are accelerating collaboration across the industry.

“With R&D and manufacturing facilities in both the U.S. and Europe, WuXi AppTec will continue investing in new technologies and platforms to better support the innovation needs of pharmaceutical companies of all sizes around the world,” they noted.

Dr. Hui Cai, Vice President of WuXi AppTec, expressed gratitude to all guests and industry leaders in attendance. She emphasized that today’s biopharmaceutical progress rests on strategic planning, continuous technological innovation, and a strong, connected ecosystem. This year marks the 25th anniversary of WuXi AppTec. Since its founding, the company has been guided by a shared vision: “Every drug can be made and every disease can be treated.”

As Volvo builds its legacy, SwedenBIO builds trusted collaboration in the Nordic ecosystem, our pharma and biotech guests build innovative therapies, and WuXi AppTec is committed to building a stronger enabling platform for our customers. Together, we build a brighter future for global health—and for patients worldwide.

免責聲明：本文僅作信息交流之目的，文中觀點不代表藥明康德立場，亦不代表藥明康德支持或反對文中觀點。本文也不是治療方案推薦。如需獲得治療方案指導，請前往正規醫院就診。

版權說明：歡迎個人轉發至朋友圈，謝絕媒體或機構未經授權以任何形式轉載至其他平臺。轉載授權請在「藥明康德」微信公眾號回復“轉載”，獲取轉載須知。